Curbside Consultation

How to Manage a Patient with Weight Regain

 

Am Fam Physician. 2020 Nov 1;102(9):567-570.

Case Scenario

A 50-year-old patient, M.W., successfully reached their goal weight by losing 15 lb (6.8 kg) over six months on a Mediterranean diet. After maintaining the weight loss for more than a year, my patient is now 30 lb (13.6 kg) over their ideal body weight of 140 lb (63.5 kg). My patient has developed cardiometabolic syndrome and receives intensive lifestyle counseling. M.W. feels ashamed by the “failure” and has been avoiding seeing a physician.

Commentary

Internalized weight bias, or self-criticism of one's weight, can cause significant distress in patients trying to lose weight1 and may be particularly pronounced in patients who have regained some or most of their original weight loss.2 An appropriate clinical response to a patient's weight regain includes validation of the patient's effort, acknowledgment of the biological set point that regulates weight as tightly as sodium or water balance,3 and a step-wise approach to weight loss that incorporates lifestyle changes, environmental factors, pharmacotherapy, and, if necessary, bariatric surgery.

To assist a patient who has experienced weight regain, the physician should acknowledge, congratulate, and build on the patient's previous commitment and success in losing weight.4 The patient should be reminded that weight regain may not be a failure of willpower but rather part of the body's innate biology to maintain weight for survival.3 Following weight loss, this drive causes an increase in appetite and produces adaptive thermogenesis, or a lower metabolic rate, compared with others who have a similar body composition; however, there are various ways to ensure long-term weight-loss success.5

To begin, the definition of successful weight loss should be clarified to the patient. For those at risk of diabetes mellitus, a 5% weight loss has shown a significant decrease in progression to diabetes, whereas a 5% to 10% weight loss is needed to see significant reductions in A1C for people who have confirmed diabetes. For most patients, a 5% weight loss results in a modest improvement in cholesterol and triglyceride levels and blood pressure.6 A 3% to 5% minimum weight loss seems necessary to improve steatosis in patients with nonalcoholic fatty liver disease, whereas a 7% to 10% weight loss is needed to improve fibrosis.7

Optimization of lifestyle with diet and activity plus behavioral support remain critical interventions in weight management after weight regain. These changes may be perceived as less difficult by focusing on the positive impact of a healthy diet rather than on dietary deprivation or extreme physical or psychosocial measures. A simple set of goals, consistent with the literature that describes how lifestyle behaviors support longevity, can be established using the 5-2-1-0 approach8  (Table 18,9).

 Enlarge     Print

TABLE 1.

Healthy Lifestyle Mnemonic 5-2-1-0

5

5 servings of fruits and vegetables per day 5% weight loss if body mass index ≥ 30 kg per m2; consider body mass index ≥ 27 kg per m2 in Asian or Asian American patients9

2

2 hours or less of nonwork screen time per day 2 drinks or less of alcohol per day for men

1

1 hour of activity per day 1 drink or less of alcohol per day for women

0

0 sweetened drinks No smoking


Information from references 8 and 9.

TABLE 1.

Healthy Lifestyle Mnemonic 5-2-1-0

5

5 servings of fruits and vegetables per day 5% weight loss if body mass index ≥ 30 kg per m2; consider body mass index ≥ 27 kg per m2 in Asian or Asian American patients9

2

2 hours or less of nonwork screen time per day 2 drinks or less of alcohol per day for men

1

1 hour of activity per day 1 drink or less of alcohol per day for women

0

0 sweetened drinks No smoking


Information from references 8 and 9.

If these strategies are ineffective, pharmacotherapy can be an appropriate next step (Table 21022). To be approved by the U.S. Food and Drug Administration (FDA) for weight loss, a medication must show at least a 5% weight loss vs. a placebo.22 Other than orlistat (Xenical), a pancreatic lipase inhibitor that works in the gastrointestinal tract to inhibit triglyceride absorption, all other anti-obesity–specific medications work through neurohormonal changes that decrease appetite.22 Currently, no medications approved by the FDA increase thermogenesis or energy expenditure. The lack of pharmacologic interventions that can affect the pathways responsible for changing the body's set point explains why medications are only modestly effective in helping maintain weight loss and combating weight regain. On average, anti-obesity medications result in a 5% to 10% weight loss, and patients should have achieved at least a 5% weight loss after three months on the maximally tolerated dose to continue taking an anti-obesity medication. Phentermine is the only weight-loss medication not approved by the FDA for long-term use. A randomized trial demonstrated that a com

Address correspondence to Ku-Lang Chang, MD, FAAFP, at changk@shands.ufl.edu. Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.

References

show all references

1. Pearl RL, Puhl RM. Weight bias internalization and health: a systematic review. Obes Rev. 2018;19(8):1141–1163....

2. Puhl RM, Quinn DM, Weisz BM, et al. The role of stigma in weight loss maintenance among U.S. adults. Ann Behav Med. 2017;51(5):754–763.

3. Lowell BB. New neuroscience of homeostasis and drives for food, water, and salt. N Engl J Med. 2019;380(5):459–471.

4. Phelan SM, Burgess DJ, Yeazel MW, et al. Impact of weight bias and stigma on quality of care and outcomes for patients with obesity. Obes Rev. 2015;16(4):319–326.

5. Fothergill E, Guo J, Howard L, et al. Persistent metabolic adaptation 6 years after “The Biggest Loser” competition. Obesity (Silver Spring). 2016;24(8):1612–1619.

6. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society [published correction appears in Circulation. 2014;129(25 suppl 2):S139–S140]. Circulation. 2014;129(25 suppl 2):S102–S138.

7. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2017;67(1):328–357.

8. Li Y, Pan A, Wang DD, et al. Impact of healthy lifestyle factors on life expectancies in the US population [published correction appears in Circulation. 2018;138(4):e75]. Circulation. 2018;138(4):345–355.

9. Joslin Diabetes Center: Asian American Diabetes Initiative. Asian BMI calculator. Accessed March 7, 2020. https://aadi.joslin.org/en/am-i-at-risk/asian-bmi-calculator

10. Ebbeling CB, Swain JF, Feldman HA, et al. Effects of dietary composition on energy expenditure during weight-loss maintenance. JAMA. 2012;307(24):2627–2634.

11. Jamshed H, Beyl RA, Della Manna DL, et al. Early time-restricted feeding improves 24-hour glucose levels and affects markers of the Circadian clock, aging, and autophagy in humans. Nutrients. 2019;11(6):1234.

12. de Cabo R, Mattson MP. Effects of intermittent fasting on health, aging, and disease [published corrections appear in N Engl J Med. 2020;382(3):298, and N Engl J Med. 2020;382(10):978]. N Engl J Med. 2019;381(26):2541–2551.

13. Paoli A, Bosco G, Camporesi EM, et al. Ketosis, ketogenic diet and food intake control: a complex relationship. Front Psychol. 2015;6:27.

14. Apolzan JW, Venditti EM, Edelstein SL, et al.; Diabetes Prevention Program Research Group. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019;170(10):682–690.

15. le Roux CW, Astrup A, Fujioka K, et al.; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial [published correction appears in Lancet. 2017;389(10077):1398]. Lancet. 2017;389(10077):1399–1409.

16. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients [published correction appears in Diabetes Care. 2004;27(3):856]. Diabetes Care. 2004;27(1):155–161.

17. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–120.

18. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2011;377(9776):1494]. Lancet. 2011;377(9774):1341–1352.

19. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.

20. Saeidi N, Meoli L, Nestoridi E, et al. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric bypass. Science. 2013;341(6144):406–410.

21. Abdeen G, le Roux CW. Mechanism underlying the weight loss and complications of Roux-en-Y gastric bypass. Review. Obes Surg. 2016;26(2):410–421.

22. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline [published correction appears in J Clin Endocrinol Metab. 2015;100(5):2135–2136]. J Clin Endocrinol Metab. 2015;100(2):342–362.

23. Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111–2120.

24. Batterham RL, Cummings DE. Mechanisms of diabetes improvement following bariatric/metabolic surgery. Diabetes Care. 2016;39(6):893–901.

25. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366(17):1577–1585.

26. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33(7):1674–1685.

27. Pories WJ. Bariatric surgery: risks and rewards. J Clin Endocrinol Metab. 2008;93(11 suppl 1):S89–S96.

This series is coordinated by Caroline Wellbery, MD, associate deputy editor.

A collection of Curbside Consultation published in AFP is available at https://www.aafp.org/afp/curbside.

Please send scenarios to Caroline Wellbery, MD, at afpjournal@aafp.org. Materials are edited to retain confidentiality.

 

 

Copyright © 2020 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions

CME Quiz

More in AFP


Editor's Collections


Related Content


More in Pubmed

MOST RECENT ISSUE


Dec 1, 2020

Access the latest issue of American Family Physician

Read the Issue


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now

Navigate this Article